surmount-1 tirzepatide trial obesity without diabetes as Compared with Semaglutide for the Treatment of SURMOUNT-5: Tirzepatide Bests Semaglutide in
Description
Consult with a healthcare provider for tailored advice and concerns
Participants taking Tirzepatide reported less shortness of breath, fatigue, and swelling of the lower legs along with more ability to exercise than those on placebo
In the pivotal SURMOUNT-1 clinical trial, participants taking the highest dose of tirzepatide achieved an average body weight reduction of up to 22.5% over 72 weeks
Change in weight-related quality of life as measured by the Impact of Weight on Quality of Life-Lite Clinical Trials Questionnaire
Tirzepatide vs
New insights on semaglutide for obesity treatment
